September 21, 2016
Unum Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
CAMBRIDGE, MA, September 21, 2016 – Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that President and Chief Executive Officer Chuck Wilson will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on September 29, 2016 at 12:30 pm ET. The conference is being held September 28-29, 2016 at the Lotte New York Palace in New York.
Unum uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The Company’s lead program, which combines Unum’s proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with rituximab, is in Phase 1 clinical testing to assess its safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.
# # #